Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

According to a new feature by the Washington Post, approximately 16 million American adults are on GLP-1 drugs such as ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Wegovy, a weight loss drug, is gaining popularity for its effectiveness, but experts emphasize that it's most successful when ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss.

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

Medication paired with behavioral change support gives employers the opportunity to provide a more well-rounded approach to ...

Weight loss drugs have become quite popular in the past years. However, there are a few aspects of the drug that need to be ...

Drugs like semaglutide, also known by the brand names Ozempic and Wegovy, have transformed how we treat obesity, but soaring demand has led to frequent supply shortages. In the US ...